Sugi Predict

Sugi Predict / Compounds / SCHEMBL3164036

SCHEMBL3164036

SCHEMBL3164036

CC(=O)O[C@]1(C(=O)CO)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR3C1 P04150 8/20 0.85
▸ PGR P06401 7/20 0.85
▸ CYP3A4 P08684 7/20 0.85
▸ AR P10275 6/20 0.85
▸ HIF1A Q16665 5/20 0.85
▸ SMN1; SMN2 Q16637 2/20 0.85
▸ ALDH1A1 P00352 2/20 0.85
▸ CYP1A2 P05177 1/20 0.85
▸ MAPT P10636 2/20 0.74
▸ ABCB11 O95342 1/20 0.74
▸ RAB9A P51151 1/20 0.74
▸ ADORA3 P0DMS8 2/20 0.73
▸ CHRM1 P11229 1/20 0.73
▸ ADRA1A P35348 1/20 0.73
▸ NR1I2 O75469 1/20 0.66
▸ NR3C2 P08235 1/20 0.66
▸ MMP1 P03956 2/20 0.63
▸ MEN1 O00255 2/20 0.62
▸ KMT2A Q03164 2/20 0.62
▸ USP2 O75604 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL93664 1.00 NR3C1 (0.85) NR3C1PGRCYP3A4ARHIF1A
SCHEMBL11600203 1.00 NR3C1 (0.85) NR3C1PGRCYP3A4ARHIF1A
SCHEMBL11875376 1.00 NR3C1 (0.85) NR3C1PGRCYP3A4ARHIF1A
SCHEMBL11125210 1.00 NR3C1 (0.85) NR3C1PGRCYP3A4ARHIF1A
SCHEMBL11125211 1.00 NR3C1 (0.85) NR3C1PGRCYP3A4ARHIF1A
SCHEMBL11600201 1.00 NR3C1 (0.85) NR3C1PGRCYP3A4ARHIF1A
SCHEMBL11748063 0.93 NR3C1 (0.85) NR3C1PGRCYP3A4ARHIF1A
SCHEMBL11755727 0.92 PGR (0.85) NR3C1PGRCYP3A4ARHIF1A
Diflorasone Diacetate SCHEMBL10599667 0.92 HIF1A (1.00) NR3C1PGRCYP3A4ARHIF1A
Diflorasone Diacetate SCHEMBL11020199 0.92 HIF1A (1.00) NR3C1PGRCYP3A4ARHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024037644-A1 PEG-MODIFIED GLUCOCORTICOID MEDICAMENT AND USE THEREOF 津药生物科技（天津）有限公司 2024-02-22 — — WO disclosed
CN-114381521-A Methods and biomarkers for efficacy prediction and assessment of OX40 agonist treatment 豪夫迈·罗氏有限公司 2022-04-22 — — CN disclosed
CN-108135875-B Methods and compositions for treating metabolic reprogramming disorders 约翰霍普金斯大学 2021-12-31 — — CN disclosed
CN-108348492-B Methods for cancer and immunotherapy using glutamine analogs 约翰霍普金斯大学 2021-09-28 — — CN disclosed
CN-112410298-A Enhanced stem cell compositions 菲特治疗公司 2021-02-26 — — CN disclosed
CN-112375734-A Enhanced stem cell compositions 菲特治疗公司 2021-02-19 — — CN disclosed
CN-108290827-B Prodrugs of glutamine analogs 约翰霍普金斯大学 2021-01-01 — — CN disclosed
CN-104066837-B Enhanced stem cell compositions 菲特治疗公司 2020-12-08 — — CN disclosed
CN-111683653-A Methods and compositions for topical delivery 伊拉斯吹斯制药有限公司 2020-09-18 — — CN disclosed
EP-3694489-A2 METHODS AND COMPOSITIONS FOR TOPICAL DELIVERY Illustris Pharmaceuticals, Inc. (US) 2020-08-19 — — EP disclosed
US-7098328-B2 Method for the preparation of 6α-fluoro corticosteroids TARO PHARMACEUTICAL INDUSTRIES LIMITED (IL) 2006-08-29 — — US disclosed
EP-1465855-A2 METHOD FOR THE PRODUCTION OF 6-ALPHA-FLUORO CORTICOSTEROIDS TARO PHARMACEUTICALS U.S.A., INC. (US) 2004-10-13 — — EP disclosed
EP-1395603-A1 PREPARATION OF FLUMETHASONE AND ITS 17-CARBOXYL ANDROSTEN ANALOGUE Hovione Limited . (CN) 2004-03-10 — — EP disclosed
US-20030162959-A1 Method for the preparation of 6alpha-fluoro corticosteroids TARO PHARMACEUTICALS U.S.A., INC. 2003-08-28 — — US disclosed
WO-2003047329-A2 METHOD FOR THE PREPARATION OF 6-ALPHA-FLUORO CORTICOSTEROIDS TARO PHARMACEUTICALS U.S.A., INC. (US) 2003-06-12 — — WO disclosed
US-6528666-B1 C3 protecting 9,11-epoxy-17,21-dihydroxy-16-methylpregna-1,4-diene-3,20-dione,21-acetate; fluorinating at 6 alpha; depro-tecting and fluorinating epoxy group; simultaneous hydrolysis and oxidative degradation with methanolic potassium hydroxide HORIONE LIMITED (HK) 2003-03-04 — — US disclosed
WO-2002100878-A1 PREPARATION OF FLUMETHASONE AND ITS 17-CARBOXYL ANDROSTEN ANALOGUE HOVIONE LIMITED (CN) 2002-12-19 — — WO disclosed
US-4478818-A Ocular preparation housing steroid in two different therapeutic forms ALZA CORPORATION (US) 1984-10-23 — — US disclosed
US-4432964-A Topical composition containing steroid in two forms released independently from polymeric carrier ALZA CORPORATION (US) 1984-02-21 — — US disclosed
US-4304765-A Ocular insert housing steroid in two different therapeutic forms ALZA CORPORATION (US) 1981-12-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162959-A1 Method for the preparation of 6alpha-fluoro corticosteroids HSD3B1, CYP2F1, HSD3B2 NR3C1 17/4885PGR 666/4885CYP3A4 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.